|
1.
|
Robert Koch-Institut und die Gesellschaft
der epidemiologischen Krebsregister in Deutschland e. V. Berlin.
Krebs in Deutschland 2003–2004 Häufigkeit und Trends. 6th edition.
2008
|
|
2.
|
Statistisches Bundesamt:
Todesursachenstatistik in Deutschland. Fachserie 12, Reihe 4,. pp.
1–114. 2008
|
|
3.
|
Deutsche Krebsgesellschaft e. V.
Krebshäufigkeit - die aktuellen Zahlen,. 2007
|
|
4.
|
Dietel M: Ovar: tumoren. Pathologie.
Remmele W: 4. 2nd edition. Springer-Verlag; Berlin Heidelberg: pp.
92–123. 1992
|
|
5.
|
Olsen CM, Cnossen J, Green AC, et al:
Comparison of symptoms and presentation of women with benign, low
malignant potential and invasive ovarian tumors. Eur J Gynaecol
Oncol. 28:376–380. 2007.PubMed/NCBI
|
|
6.
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Goff BA, Muntz HG, Greer BE, et al:
Oncogene expression: long-term compared with short-term survival in
patients with advanced epithelial ovarian cancer. Obstet Gynecol.
92:88–93. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Kaern J, Aghmesheh M, Nesland JM, et al:
Prognostic factors in ovarian carcinomas stage III patients. Can
biomarkers improve the prediction of short- and long-term
survivors? Int J Gynecol Cancer. 15:1014–1022. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Schindlbeck C, Hantschmann P, Zerzer M, et
al: Prognostic impact of KI67, p53, human epithelial growth factor
receptor 2, topoisomerase IIalpha, epidermal growth factor
receptor, and nm23 expression of ovarian carcinomas and
disseminated tumor cells in the bone marrow. Int J Gynecol Cancer.
17:1047–1055. 2007. View Article : Google Scholar
|
|
10.
|
Faggad A, Darb-Esfahani S, Wirtz R, et al:
Topoisomerase IIalpha mRNA and protein expression in ovarian
carcinoma: correlation with clinicopathological factors and
prognosis. Mod Pathol. 22:579–588. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
De Graeff P, Crijns AP, de Jong S, et al:
Modest effect of p53, EGFR and Her-2/neu on prognosis in epithelial
ovarian cancer: a meta-analysis. Br J cancer. 101:149–159.
2009.PubMed/NCBI
|
|
12.
|
Wang JC: Cellular roles of DNA
topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol.
3:430–440. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
13.
|
World Health Organization: Pathology &
Genetics. Tumours of the Breast and Female Genital Organs. IARC
Press; Lyon: 119. 2003
|
|
14.
|
Wolff AC, Hammond ME, Schwartz JN, et al:
American Society of Clinical Oncology/College of American
Pathologists guideline recommendations for human epidermal growth
factor receptor 2 testing in breast cancer. Arch Pathol Lab Med.
131:18–43. 2007.
|
|
15.
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohisto-chemical estrogen receptor detection (ER-ICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.(In German).
|
|
16.
|
Chekerov R, Klaman I, Zafrakas M, et al:
Altered expression pattern of topoisomerase IIα in ovarian tumor
epithelial and stromal cells after platinum-based chemotherapy.
Neoplasia. 8:38–45. 2006.
|
|
17.
|
Pauletti G, Godolphin W, Press MF, et al:
Detection and quantitation of HER-2/neu gene amplification in human
breast cancer archival material using fluorescence in situ
hybridization. Oncogene. 13:63–72. 1996.PubMed/NCBI
|
|
18.
|
Cappuzzo F, Hirsch FR, Rossi E, et al:
Epidermal growth factor receptor gene and protein and gefitinib
sensitivity in non-small-cell lung cancer. J Natl Cancer Inst.
97:643–655. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Serrano-Olvera A, Duenas-Gonzalez A,
Gallardo-Rincón D, et al: Prognostic, predictive and therapeutic
implications of HER2 in invasive epithelial ovarian cancer. Cancer
Treat Rev. 32:180–190. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Lee ES, Lee Y, Suh D, et al: Detection of
HER-2 and EGFR gene amplification using chromogenic in-situ
hybridization technique in ovarian tumors. Appl Immunohistochem Mol
Morphol. 18:69–74. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Vermeij J, Teugels E, Bourgain C, et al:
Genomic activation of the EGFR and HER2-neu genes in a significant
proportion of invasive epithelial ovarian cancers. BMC cancer.
8:32008. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Dimova I, Raicheva S, Dimitrov R, et al:
Coexistence of copy number increases of c-Myc, ZNF217, CCND1, ErbB1
and ErbB2 in ovarian cancers. Onkologie. 32:405–410. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
De Graeff P, Crijns AP, Ten Hoor HK, et
al: The ErbB signalling pathway: protein expression and prognostic
value in epithelial ovarian cancer. Br J Cancer. 99:341–349.
2008.PubMed/NCBI
|
|
24.
|
Farley J, Fuchiuji S, Darcy KM, et al:
Associations between ERBB2 amplification and progression-free
survival and overall survival in advanced stage,
suboptimally-resected epithelial ovarian cancers: a Gynecologic
Oncology Group Study. Gynecol Oncol. 113:341–347. 2009. View Article : Google Scholar
|
|
25.
|
Durbecq V, Paesmans M, Cardoso F, et al:
Topoisomerase-II alpha expression as a predictive marker in a
population of advanced breast cancer patients randomly treated
either with single-agent doxorubicin or single-agent docetaxel. Mol
Cancer Ther. 3:1207–1214. 2004.
|
|
26.
|
Schindlbeck C, Mayr D, Olivier C, et al:
Topoisomerase IIalpha expression rather than gene amplification
predicts responsiveness of adjuvant anthracycline-based
chemotherapy in women with primary breast cancer. J Cancer Res Clin
Oncol. 136:1029–1037. 2010. View Article : Google Scholar
|
|
27.
|
Lassus H, Sihto H, Leminen A, et al: Gene
amplification, mutation, and protein expression of EGFR and
mutations of ERBB2 in serous ovarian carcinoma. J Mol Med.
84:671–681. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Tanaka Y, Terai Y, Tanabe A, et al:
Prognostic effect of epidermal growth factor receptor gene
mutations and the aberrant phosphorylation of Akt and ERK in
ovarian cancer. Cancer Biol Ther. 11:50–57. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Stadlmann S, Gueth U, Reiser U, et al:
Epithelial growth factor receptor status in primary and recurrent
ovarian cancer. Mod Pathol. 19:607–610. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Tanner B, Hasenclever D, Stern K, et al:
ErbB-3 predicts survival in ovarian cancer. J Clin Oncol.
24:4317–4323. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Garcia-Velasco A, Mendiola C,
Sanchez-Munoz A, et al: Prognostic value of hormonal receptors,
p53, ki67 and Her2/neu expression in epithelial ovarian carcinoma.
Clin Transl Oncol. 10:367–371. 2008. View Article : Google Scholar : PubMed/NCBI
|
